Bill
S 734
The bill creates a state specialty pharmacy license for in‑state, non‑mail pharmacies, requires a licensed pharmacist in charge, and ensures insurers cover and allow dispensing by
Status (as provided)
- Introduced: 1/14/2025 (Senate Docket No. 621).
- Current procedural note: Referred to committee; a public hearing is scheduled for 06/10/2025 (10:30 AM–1:00 PM).
- Sponsor according to the bill text: Senator James B. Eldridge (Middlesex & Worcester). (The separate sponsor list in the supplied metadata appears inconsistent with the bill text and may refer to different or related measures.)
Purpose
- To increase state oversight of pharmacies that dispense specialty medications and to ensure insured patients in the Commonwealth have access to specialty drugs from licensed, in‑state specialty pharmacies (excluding mail service pharmacies). The bill also limits insurers' ability to restrict which licensed pharmacies may dispense specialty drugs covered under a plan.
Key provisions
1. New licensing requirement (Chapter 112 — new Section 39K)
- Creates a specialty pharmacy license for any pharmacy dispensing specialty medications in the Commonwealth; explicitly excludes mail service pharmacies from the “specialty pharmacy” definition.
- Requires designation and registration of a “pharmacist in charge” who is licensed and in good standing in the jurisdiction where the pharmacy is located.
- Requires submission of the pharmacist in charge’s identification, managers’ names, and an annual certification of good standing and licensing, plus notification within 30 days of changes.
- Requires annual certification that the pharmacy maintains records of all drugs dispensed to patients in the Commonwealth and submission of a list of drugs dispensed in-state. Pharmacies must notify the board of any enforcement/disciplinary action (even if taken by another state).
- Prohibits pharmacies or pharmacists operating outside the Commonwealth from prescribing, shipping, mailing, selling, transferring or dispensing drug preparations in the Commonwealth unless they hold the specialty pharmacy license.
- Grants the Division of Insurance authority to adopt implementing policies/regulations.
Who would be affected
- In‑state pharmacies dispensing specialty medications: would need to obtain specialty pharmacy licensure, designate a registered pharmacist in charge, maintain specific records and report annually.
- Out‑of‑state pharmacies and mail service pharmacies: out‑of‑state pharmacies would be barred from dispensing into the Commonwealth unless licensed under the new regime; mail service pharmacies are excluded from the specialty‑pharmacy definition (but the bill’s prohibition language targets out‑of‑state pharmacies).
- Insurers, pharmacy benefit managers (PBMs), and provider networks: would be restricted from steering or prohibiting covered specialty drug dispensing to any licensed pharmacy that meets handling requirements and agrees to reimbursement terms.
- Patients: likely increased local access to specialty drugs from licensed in‑state pharmacies; potential changes to mail‑order access depending on carrier practices.
Potential impacts and considerations
- Could increase regulatory oversight and administrative burden for pharmacies (licensing, recordkeeping, reporting).
- May limit insurers’ and PBMs’ ability to funnel specialty prescriptions to a limited set of specialty pharmacies, potentially expanding patient choice and local access but affecting existing specialty‑pharmacy business models and network arrangements.
- Enforcement and operational details would depend on regulations the Division of Insurance issues.
Procedural/timeline notes
- Inserted as Section 39K in Chapter 112 and a conforming amendment to Chapter 176D, §3B. Public hearing scheduled 06/10/2025 per the provided legislative actions.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
